Polyclonal Antibody to Tumor Necrosis Factor Receptor Superfamily, Member 1B (TNFRSF1B)
| Code | Size | Price |
|---|
| PAB504Hu01-20ul | 20ul | £84.00 |
Quantity:
| PAB504Hu01-100ul | 100ul | £155.00 |
Quantity:
| PAB504Hu01-200ul | 200ul | £208.00 |
Quantity:
| PAB504Hu01-1ml | 1ml | £475.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD120B; P75; TBPII; TNF-R-II; TNF-R75; TNFBR; TNFR2; TNFR80; P75tnfr; Tumor necrosis factor receptor 2; p80 TNF-alpha receptor; Etanercept
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Tumor Necrosis Factor Receptor Superfamily, Member 1B
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Tumor Necrosis Factor Receptor Superfamily, Member 1B (TNFRSF1B) | RPB504Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||